Valuation: ImmunityBio, Inc.

Capitalization 836.5Cr 711.7Cr 652.76Cr 619.28Cr 1.14TCr 78TCr 1.17TCr 7.66TCr 3.02TCr 38TCr 3.14TCr 3.07TCr 1,33400Cr P/E ratio 2026 *
-31.4x
P/E ratio 2027 * -140x
Enterprise value 836.5Cr 711.7Cr 652.76Cr 619.28Cr 1.14TCr 78TCr 1.17TCr 7.66TCr 3.02TCr 38TCr 3.14TCr 3.07TCr 1,33400Cr EV / Sales 2026 *
39.9x
EV / Sales 2027 * 17.3x
Free-Float
21.9%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week+6.58%
Current month+5.61%
1 month-4.37%
3 months+17.05%
6 months+231.97%
Current year+309.09%
1 week 7.12
Extreme 7.12
8.56
1 month 6.54
Extreme 6.54
9.54
Current year 1.98
Extreme 1.98
12.43
1 year 1.83
Extreme 1.83
12.43
3 years 1.25
Extreme 1.25
12.43
5 years 1.21
Extreme 1.21
19.72
10 years 1.21
Extreme 1.21
40.83
Manager TitleAgeSince
Chief Executive Officer 57 01/10/2020
Chief Executive Officer 73 01/03/2015
Director of Finance/CFO 48 01/03/2021
Director TitleAgeSince
Director/Board Member 71 01/03/2021
Chairman 73 01/12/2014
Director/Board Member 57 29/03/2021
Change 5d. change 1-year change 3-years change Capi.($)
-1.22%+6.58%+222.71%+202.24% 846.83Cr
-3.00%-2.64%+30.94%+94.45% 5.19TCr
-1.21%-7.51%+82.87%+28.98% 4.43TCr
-1.29%-8.10%+102.82%+673.77% 3.08TCr
+6.09%+13.40%+9.62%-5.65% 2.66TCr
+5.02%+26.52%+4.60%+1,580.25% 1.95TCr
+0.17%-4.16%+62.69%-29.67% 1.88TCr
+1.77%+1.29%+68.89%+250.47% 1.73TCr
-2.42%-6.02%+34.11%-37.90% 1.72TCr
-0.94%-4.12%+65.87% - 1.51TCr
Average +0.25%+4.39%+68.51%+306.33% 2.5TCr
Weighted average by Cap. -0.13%+1.67%+58.53%+265.85%

Financials

2026 *2027 *
Net sales 21Cr 18Cr 16Cr 16Cr 29Cr 1.96TCr 29Cr 191.93Cr 76Cr 940.25Cr 79Cr 77Cr 3.34TCr 48Cr 41Cr 38Cr 36Cr 66Cr 4.53TCr 68Cr 443.64Cr 174.6Cr 2.17TCr 181.61Cr 177.86Cr 7.72TCr
Net income -26Cr -22Cr -20Cr -19Cr -35Cr -2.4TCr -36Cr -234.66Cr -92Cr -1.15TCr -96Cr -94Cr -4.08TCr -6.02Cr -5.12Cr -4.69Cr -4.45Cr -8.21Cr -562.78Cr -8.39Cr -55Cr -22Cr -270.05Cr -23Cr -22Cr -959.04Cr
Net Debt - -
Logo ImmunityBio, Inc.
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Employees
688
Date Price Change Volume
21/26/21 8.100 $ -1.22% 1,31,52,612
20/26/20 8.200 $ +6.49% 1,62,11,232
17/26/17 7.700 $ +6.21% 2,15,20,488
16/26/16 7.250 $ -6.81% 1,75,52,938
15/26/15 7.780 $ +2.37% 1,05,24,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.100USD
Average target price
14.80USD
Spread / Average Target
+82.72%

Quarterly revenue - Rate of surprise